Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia.
- Author:
Qing-feng DU
1
;
Song ZHANG
;
Xiao-li LIU
;
Fang-yi MENG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Antineoplastic Agents; therapeutic use; Benzamides; Child; Female; Fusion Proteins, bcr-abl; genetics; Genes, abl; genetics; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; methods; Interphase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; drug therapy; genetics; pathology; Male; Middle Aged; Piperazines; therapeutic use; Pyrimidines; therapeutic use; Sensitivity and Specificity; Tumor Burden; drug effects; Young Adult
- From: Journal of Southern Medical University 2010;30(1):123-125
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the sensitivity and specificity of dual-color and dual-fusion interphase fluorescence in situ hybridization (D-FISH) in determining the tumor load in patients with chronic myeloid leukemia (CML) receiving imatinib therapy.
METHODSThe BCR-ABL fusion gene was detected by FISH in 24 cases of chronic myeloid leukemia treated with imatinib. The sensitivity and specificity of D-FISH were compared with those of single-fusion FISH (S-FISH) and RT-PCR.
RESULTSD-FISH was more sensitive and specific than S-FISH. In normal control subjects, the cutoff rates of D-FISH and S-FISH were 0.73% and 6.24%, respectively, showing a significant difference between them. In 24 CML cases receiving imatinib treatment, the positivity rates of S-FISH and D-FISH were 7/24 (29.2%) and 13/24 (54.2%), respectively. The results of D-FISH had a high correlation to that of RT-PCR.
CONCLUSIONWith lower false positive and false negative results, D-FISH can be used as a sensitive and specific method for monitoring the changes of the tumor load in CML patients during imatinib treatment.
